Our results showed that blocking LIGHT-HVEM/LTβR pathway alleviates I/R-induced kidney injury, which further supports the potential clinical efficacy of LIGHT inhibitors for I/R-AKI in humans. The gene discussed is LTBR; the disease is kidney injury.